Barely Significant
← all excerpts

[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

PLoS One · 2014 · PMC3914822 · PMID 24505298

Europe PMCDOI
1
hedged sentence
0.0200
closest p · 0.4× alpha
0.0200
boldest claim

The sentences

highly significantp = 0.02actually significant
[36] In a similar group of NSCLC patients, the results of the TAILOR trial indicated a highly significant increase of PFS in favor of docetaxel (HR = 0.71; 95% CI, 0.53–0.95; p = 0.02) versus erlotinib.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.